For example, high FZD10, MKX, FAM83A and MYO18B methylation were related with response to platinum-based chemotherapy in advanced stage high-grade serous ovarian cancer (HGSOC), and these markers might be used to predict platinum sensitivity in HGSOC patients (Tomar et al., 2017). This evidence concerns the gene MKX and ovarian serous adenocarcinoma.